Department of Surgery, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Laboratory of Data Discovery for Health (D24H), Hong Kong SAR, China.
World J Surg. 2024 Feb;48(2):393-407. doi: 10.1002/wjs.12066. Epub 2024 Jan 18.
This network meta-analysis aimed to evaluate the association of anti-thyroid drugs (ATD), radioactive iodine (RAI), and thyroidectomy with subsequent outcomes in patients with newly-diagnosed hyperthyroidism.
The Ovid Medline, Ovid Embase, and Cochrane Library databases were searched for observational studies and randomized controlled trials. Included studies were published on or before 1st May 2022 involving at least two of the treatments among ATD, RAI, and thyroidectomy for hyperthyroidism. Pairwise comparisons and Bayesian network meta-analysis were used to estimate hazard ratios (HRs) and their credible interval (CrI) of outcomes, including cardiovascular disease (CVD), cancer, overall mortality, and Graves' ophthalmopathy (GO).
A total of 22 cohort studies with 131,297 hyperthyroidism patients were included. Thyroidectomy was associated with lower risks of mortality and GO than ATD (HR = 0.54, 95% CrI: 0.31, 0.96; HR = 0.31, 95% CrI: 0.12, 0.64) and RAI (HR = 0.62, 95% CrI: 0.41, 0.95; HR = 0.18, 95% CrI: 0.07, 0.35). RAI had a higher risk of GO (HR = 1.70, 95% CrI: 1.02, 2.99) than ATD treatment.
This Bayesian network meta-analysis indicated that thyroidectomy was associated with lower risks of mortality and GO in newly-diagnosed hyperthyroid patients compared to ATD and RAI. Relative to ATD, RAI therapy increased the risk of GO.
本网络荟萃分析旨在评估抗甲状腺药物(ATD)、放射性碘(RAI)和甲状腺切除术与新发甲状腺功能亢进症患者后续结局的相关性。
检索 Ovid Medline、Ovid Embase 和 Cochrane 图书馆数据库,纳入发表于 2022 年 5 月 1 日之前的观察性研究和随机对照试验,至少纳入 ATD、RAI 和甲状腺切除术治疗甲状腺功能亢进症的两种以上治疗方法的研究。采用成对比较和贝叶斯网络荟萃分析来评估结局(包括心血管疾病(CVD)、癌症、总死亡率和格雷夫斯眼病(GO))的风险比(HR)及其可信区间(CrI)。
共纳入 22 项队列研究,共纳入 131297 例甲状腺功能亢进症患者。与 ATD(HR=0.54,95%CrI:0.31,0.96;HR=0.31,95%CrI:0.12,0.64)和 RAI(HR=0.62,95%CrI:0.41,0.95;HR=0.18,95%CrI:0.07,0.35)相比,甲状腺切除术与较低的死亡率和 GO 风险相关。与 ATD 治疗相比,RAI 治疗发生 GO 的风险更高(HR=1.70,95%CrI:1.02,2.99)。
本贝叶斯网络荟萃分析表明,与 ATD 和 RAI 相比,甲状腺切除术与新发甲状腺功能亢进症患者的死亡率和 GO 风险降低相关。与 ATD 相比,RAI 治疗增加了 GO 的风险。